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Evaluating Patient’s Knowledge Regarding Opioid Prescriptions in An
Independent Community Pharmacy: A Pilot Study
Lauren Chars, PharmD
Patricia Devine, PharmD
Tyler Girton, PharmD
Abstract: This study evaluated patients’ knowledge regarding their opioid prescriptions and identified what resources were used to educate patients
on their opioid prescriptions. Patients receiving an opioid prescription from an independent pharmacy were given a link to complete a nine-question
anonymous survey about their awareness of their prescription being an opioid, how and what education they received, and from whom. The authors
hope that the findings of this research will help to better understand effective ways to combat the opioid epidemic and promote patient safety
through effective opioid education.

A

ccording to the Centers for Disease Control and Prevention,
deaths due to synthetic opioids other than methadone, natural
and semisynthetic opioids, and heroin have been increasing from
1999 to 2017.1 Approximately 92 million people in the United States use
opioid pain relievers, and 11.5% of these individuals misuse the
medications.2,3 Furthermore, over 47,000 opioid-related overdose
deaths occurred in the United States in 2017. 4
In an effort to curb opioid addiction, dependence, and deaths, many
regulations have been enacted regarding opioid prescriptions. On a
national level, the Centers for Disease Control and Prevention has
published guidelines informing providers on how to prescribe opioids
for chronic pain.5 Currently, there is a lack of federal guidance and a
scarcity of state regulations requiring patient labeling stating that
medications are opioids.6 This is evident in that only five states have
passed regulations mandating auxiliary stickers to be affixed to
prescription bottles containing opioids.7-12 Education is a key
component to patient awareness in regard to opioid medications. In a
prior study by de la Cruz et al., palliative care patients were separated
into groups where one group received educational materials
surrounding safe opioid usage, storage, and disposal with each opioid
prescription, whereas the other group did not receive these materials.
The group that received the educational materials were more likely to
keep their medications protected in a safe place while being more aware
of proper opioid disposal methods. Additionally, this group was less
likely to share their prescription with others, practice unsafe usage of
opioids, or have unused medication at home. 13
Medical providers and pharmacists can play a critical role in providing
meaningful education through verbal counseling. Moreover,
pharmacists can provide written education to patients to enhance the
retention of important information. The use of auxiliary labels and
medication guides can provide time-saving methods for outpatient
pharmacists to distribute information about prescription medications,
but the extent of the benefit of these forms of communication remains
controversial.14-17 One medication brochure study, Wolf et al., shows
that of the studied FDA-approved medication guides, all were above the
recommended sixth through eighth grade reading level and often failed
to provide a summary of the content to help increase understanding of
the content in the guide.14 Furthermore, another study by Wolf et al.
demonstrated that of the participants who read the medication guide
and were asked information retrieval or inference questions, the
average participant could only recall approximately half of the
information in the medication guide.15

Regarding auxiliary labels, results are more positive. In a study by GryfeBecker et al., when providing elderly patients with either an auxiliary
label and counseling, an auxiliary label without counseling, counseling
without an auxiliary label, or no counseling nor auxiliary label, it was
found that individuals who received auxiliary labels were better able to
correctly and completely recall the information on the label as opposed
to the group that received no label or counseling (p=0.018).16
Furthermore, in a study conducted by Brown et al. in patients who
received additional auxiliary labels, 13.2% more patients were able to
recall questions about their medication compared to subjects who did
not receive an additional auxiliary label.17
Our study sought to provide patients who were picking up prescriptions
for opioids in an independent community pharmacy setting with
additional information regarding their medications. Patients were
provided with an auxiliary label on their prescription bottles detailing
that a medication was an opioid and an educational opioid brochure.
The purpose of this study was to evaluate patients’ knowledge regarding
their opioid prescriptions and to assess what resources educated these
patients on their opioid prescriptions. A literature search in Google
Scholar and PubMed was conducted to find studies similar to that of our
design. To the authors’ knowledge, this is the first study to evaluate
patient knowledge and to assess the methods by which patients receive
education regarding their opioid prescriptions.
Methods
A descriptive analysis study in 2019 was conducted. The development of
an anonymous nine question Skip Logic survey on QualtricsTM (version
2015) was created by the researchers and provided to eight healthcare
providers to pilot the survey and provide feedback on content, question
understanding, and ease of use. Through examination of responses,
questions were refined, removed, or remained for the final survey.
The study was conducted at an independent community pharmacy in
spring 2019 and was approved by the Institutional Review Board of
Butler University. Patients using this pharmacy who were at least 18
years old and received at least one opioid prescription during this time
period were eligible for inclusion in the study. An auxiliary label stating,
“High-Risk Medication OPIOID” was affixed to the opioid prescription
bottle to inform patients that their prescriptions were opioids. Patients
were given an educational brochure to inform them about the effects,
storage, alternative treatments, and proper methods for discarding
unused opioid medications. Patients were contacted after one week of
receiving their prescriptions to complete an anonymous nine question
Skip Logic QualtricsTM survey. Patients completing the survey answered
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questions regarding demographics, knowledge of opioids, the prescriber
of their prescriptions, and how they were educated about their opioid
prescriptions. A maximum of three attempts were made to reach
patients by telephone. Descriptive analyses were conducted to generate
results.
Results
Eighteen of the nineteen patients contacted completed the survey for a
response rate of 94.7%. The full quantitative question set used in the
survey along with the responses obtained is reported below in Table 1.
Table 1. Quantitative Survey questions with responses
Question

Survey Responses (Percent) n=18 patients

1. Are you aware that a
medication of yours is an
opioid?
2. Who prescribed you your
opioid pain medication?

Yes-17 (94.4%)
No- 0 (0%)
Prefer not to respond-1 (5.6%)
Physician- 16 (88.9%)
Physician Assistant- 0 (0%)
Nurse Practitioner- 1 (5.6%)
Dentist- 0 (0%)
Other- 1 (5.6%)
I don’t know- 0 (0%)
Prefer not to respond- 0 (0%)
Prescriber- 8 (44.4%)
Pharmacist- 5 (27.8%)
Opioid sticker on bottle- 3 (16.7%)
Opioid brochure- 0 (0%)
Family member or friend- 1 (5.6%)
Caregiver- 0 (0%)
Other- 6 (33.3%)
I was not made aware that a medication was an
opioid- 0 (0%)
Prefer not to respond- 0 (0%)
Physician- 10 (55.6%)
Pharmacist- 3 (16.7%)
Opioid brochure- 0 (0%)
Family member or friend- 0 (0%)
Caregiver- 0 (0%)
Other- 6 (33.3%)
I was not educated on my opioid medication- 3
(16.7%)
Prefer not to respond- 0 (0%)
What an opioid is- 8 (44.4%)
How/when to take your medication- 9 (50%)
Alternative non-opioid medications for pain- 2 (11.1%)
Alternative non-medication treatments for pain- 3
(16.7%)
How to store your medication- 3 (16.7%)
How to dispose of your medication- 3 (16.7%)
Side effects of your medication- 7 (38.9%)
Other- 3 (16.7%)
None of the above/I was not educated on this
medication- 2 (11.1%)
Prefer not to respond- 0 (0%)
Prescriber- 8 (44.4%)
Pharmacist- 7 (38.9%)
Opioid brochure- 0 (0%)
Family member or friend- 0 (0%)
Caregiver- 0 (0%)
Other- 2 (11.1%)
I did not have any medication questions- 3 (16.7%)
My medication questions were not answered- 0 (0%)
Prefer not to respond- 0 (0%)
Yes- 12 (66.7%),
No- 5 (27.8%),
Prefer not to respond- 1 (5.6%)
18-25- 1 (5.6%)
26-39- 3 (16.7%)
40-65- 8 (44.4%)
65+- 6 (33.3%)
Prefer not to respond- 0 (0%)

3. How were you made
aware that your medication
was an opioid? (Select all
that apply)

4. Who/what educated you
on your opioid
medication? (Select all that
apply)

5. What were you educated
on regarding your
medication? (Select all that
apply)

6. Who/what answered your
questions regarding your
medication? (Select all that
apply)

7. Do you have Medicare?

8. What is your age?

In this study, patients were assessed on awareness of their opioid
prescriptions, followed by who was involved in their care and what
education they received. Almost all patients were aware that the
medications they were taking were opioids, with 94.4% acknowledging
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this fact and 5.6% choosing not to respond. When asked who prescribed
the medication, the majority of patients responded from a physician
(88.9%) with one response each for nurse practitioner (5.6%) and
oncologist pain specialist (5.6%). Patients were asked to select all the
methods they were made aware of the medication being an opioid.
Being informed by a prescriber (44.4%) was the top selection, followed
by pharmacist (27.8%), the opioid auxiliary sticker (16.7%), and being
told by family and friends (5.6%). Six respondents choose other and selfreported general knowledge, life experience, and prior long-term use of
the medication as the method of being made aware the medication was
an opioid. Regarding how they obtained education about the product,
55.6% reported the physician and 16.7% reported education provided
by the pharmacist. Three (16.7%) of the patients who selected “Other”
reported self-education, and three (16.7%) selected they were not
educated on their opioid medication. The top two education topics
respondents selected were how to take the medication and what is an
opioid (complete results are in Table 1, question 5). When patients
asked questions about their opioids, physicians (44.4%) and pharmacists
(38.9%) were the top answers. When asked what additional comments
and questions patients had, one patient reported attempting to taper
their hydrocodone prescription unsuccessfully, commenting that they
started taking opioids 30 years ago when there was no awareness
training at that time, and one patient asked about how long opioids stay
in the body.
Discussion
The results of this study agree with the findings of similar studies in this
field while also validating legislative efforts on improving patient safety.
This study indicates that opioid auxiliary stickers provided opioid
awareness. This finding was similar to the findings of the study
performed by de la Cruz et al.13 In addition, various legislative actions
have taken place on a state and national level to improve opioid
awareness with the requirement of labeling now mandatory by law. At
least 5 states have passed legislation requiring opioid warning labels,
and the Lessening Addiction by Enhancing Labeling (LABEL) Opioids Act
was introduced as a bill in the United States Congress in May 2019 (H.R.
2732).6-12
Despite the benefits of written education, verbal patient education by
health care providers was shown to be more important for enhancing
awareness surrounding opioid prescriptions. This result highlights the
importance of health care providers educating their patients about
important medication information, including communicating risks and
ensuring safe usage of these prescriptions. While this study reinforces
the benefits of auxiliary stickers, it casts a more questionable light on
pamphlets as a beneficial source of education. The authors of this study
hypothesize that this may be due to patients not reading brochures
because of their excessive length. Previous studies have questioned the
utility and efficacy of medication guides, and this study also questions
the benefits of patient-centered brochures in providing meaningful
patient education.15 In the future, healthcare practitioners may want to
emphasize using brief yet concise written resources to educate patients
on their opioid medications.
A concern found in this study was that 16.7% of the patients were not
educated regarding their opioid medications and another 16.7%
patients claimed they discovered their medications were opioids by
personal research. Patients may seek information on the internet
instead of evidence-based information provided to them by a health
care practitioner. Overall, this study reinforces the necessity of direct
patient communication from a health care professional and the use of
auxiliary labels. However, there are some limitations in this study. The
small number of participants limits the generalizability of the results.
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The study did not differentiate whether the patient’s opioid prescription
was a first-time fill or a refill. Future research with a larger sample size
involving multiple pharmacies and additional information, including
where patients obtain information online and if the prescription was a
first-time fill or refill, is needed.
Conclusion
This study found that a majority of patients were aware their medication
was an opioid. While the auxiliary sticker aided in making patients
aware of their opioid prescription, health care professionals such as
prescribers and pharmacists played the larger role in providing this
awareness and educating the patients. Furthermore, although the
brochures contained important content, no patient reported using this
as a resource for education. Findings suggest direct communication
from health care professionals play the major role in educating patients
on opioid medications. Health profession schools should emphasize
opioid education and counseling. Findings from this study and
subsequent studies could encourage further legislation and regulation
of opioid labeling to inform consumers about their prescriptions.
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